Amgen
Fighting the World's Toughest Diseases
Amgen harnesses the best of biology and technology to make people's lives easier, fuller, and longer.
As an American biotechnology company serving patients around the world, continued investment in the U.S. — through public-private partnerships, venture capital support of start-ups, and our own homegrown research and development and manufacturing capabilities — is foundational to our ability to innovate and create cutting-edge science.
Pro-growth tax policies made possible by the Tax Cuts and Jobs Act and made permanent in the One Big Beautiful Bill Act, have enabled Amgen to invest $40 billion in U.S. innovation and manufacturing since 2018.
Amgen recently announced a $600 million investment at its headquarters in Thousand Oaks, California, for a new center for science and innovation. Additional major investments include $1 billion in North Carolina, $900 million in Ohio and an additional $650 million in Puerto Rico to support increased production of biologic medicines.
"This is an extraordinary time for biotechnology. Science and technology are accelerating the cadence of innovation."Robert A. Bradway, Amgen CEO
A Biotech Leader
Amgen helped establish the biotechnology industry more than 40 years ago and we remain on the cutting-edge of innovation, using technology and human genetic data to push beyond what’s known today.
Our investment in research and development has yielded a robust pipeline that builds on our existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.
Science & Innovation
Making Medicines Safely & Reliably
Operating Responsibly
Making a positive difference in the world is at the heart of what we do at Amgen — and it goes beyond making vital medicines.
We also help build a better world by being a good corporate citizen.
We focus on four therapeutic areas, delivering innovative medicines to help people live easier, fuller, and longer lives.
